US FDA Declines to Approve Outlook’s Eye Disease Drug for Second Time in 2025

by Medscape • 2025/12/31 • 0 Comments

Outlook Therapeutics said on Wednesday the U.S. health regulator has declined to approve its drug for a type of eye disease, dealing ‌another blow in the company's prolonged...
Reuters Health Information

← AmblyoPlay improves visual acuity, hand-eye coordination

7MM Diabetic Macular Edema (DME) Epidemiology Forecast Report 2024-2034: Focus on US, France, Germany, Italy, Spain, UK, and Japan – ResearchAndMarkets.com →

Post navigation